Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 5/20 | 0.56 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | EGFR | P00533 | 1/20 | 0.56 |
| ▸ | LCK | P06239 | 1/20 | 0.56 |
| ▸ | FYN | P06241 | 1/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | HTR2A | P28223 | 1/20 | 0.56 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | PTPRC | P08575 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20921973 | 1.00 | SLC7A5 (0.56) | SLC7A5PTGS1KDM4EUSP2EGFR | |
| SCHEMBL17693595 | 0.90 | ALOX15 (0.43) | SLC7A5PTGS1KDM4EUSP2EGFR | |
| SCHEMBL17693640 | 0.90 | SLC7A5 (0.56) | SLC7A5PTGS1KDM4EUSP2EGFR | |
| SCHEMBL21574914 | 0.90 | SLC7A5 (0.56) | SLC7A5PTGS1KDM4EUSP2EGFR | |
| SCHEMBL17685909 | 0.87 | ALDH1A1 (0.46) | SLC7A5PTGS1KDM4EUSP2EGFR | |
| SCHEMBL17685908 | 0.87 | ALDH1A1 (0.46) | SLC7A5PTGS1KDM4EUSP2EGFR | |
| SCHEMBL9108309 | 0.84 | SLC7A5 (0.61) | SLC7A5PTGS1KDM4EUSP2EGFR | |
| SCHEMBL28441906 | 0.84 | SLC7A5 (0.61) | SLC7A5PTGS1KDM4EUSP2EGFR | |
| SCHEMBL28440219 | 0.84 | SLC7A5 (0.49) | SLC7A5PTGS1KDM4EUSP2EGFR | |
| SCHEMBL20921829 | 0.81 | SLC7A5 (0.57) | SLC7A5PTGS1KDM4EUSP2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024338-A1 | CARBIDOPA AND L-DOPA PRODRUGS AND METHODS OF USE | ABBVIE INC (US) | 2024-01-25 | — | — | US | disclosed |
| US-20240024338-A1 | CARBIDOPA AND L-DOPA PRODRUGS AND METHODS OF USE | ABBVIE INC (US) | 2024-01-25 | — | — | US | disclosed |
| EP-4186510-A1 | INTERMEDIATES AND PROCESS FOR PREPARING L-DOPA DIPHOSPHATE | AbbVie Inc. (US) | 2023-05-31 | — | — | EP | disclosed |
| US-20230157985-A1 | METHODS FOR TREATMENT OF PARKINSON'S DISEASE | NEURODERM, LTD. (IL) | 2023-05-25 | — | — | US | disclosed |
| US-20220153765-A1 | METHODS OF TREATING PARKINSON'S DISEASE | ABBVIE INC. | 2022-05-19 | — | — | US | disclosed |
| US-11091507-B2 | Methods of treating Parkinson's disease | ABBVIE INC. (US) | 2021-08-17 | — | — | US | disclosed |
| US-20200262852-A1 | CARBIDOPA PRODRUGS | ABBVIE INC. | 2020-08-20 | — | — | US | disclosed |
| US-10730895-B2 | Carbidopa prodrug | ABBVIE INC. (US) | 2020-08-04 | — | — | US | disclosed |
| EP-3569587-A1 | INTERMEDIATES AND PROCESS FOR PREPARING L-DOPA DIPHOSPHATE | AbbVie Inc. (US) | 2019-11-20 | — | — | EP | disclosed |
| EP-3209302-B1 | CARBIDOPA AND L-DOPA PRODRUGS AND THEIR USE TO TREAT PARKINSON'S DISEASE | ABBVIE INC (US) | 2019-04-24 | — | — | EP | disclosed |
| US-10174061-B2 | Carbidopa and L-dopa prodrugs and methods of use | ABBVIE INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180079762-A1 | Carbidopa and L-Dopa Prodrugs and Methods of use | ABBVIE INC. (US) | 2018-03-22 | — | — | US | disclosed |
| US-20180079762-A1 | Carbidopa and L-Dopa Prodrugs and Methods of use | ABBVIE INC. (US) | 2018-03-22 | — | — | US | disclosed |
| US-20160362431-A1 | Carbidopa And L-Dopa Prodrugs And Methods Of Use | ABBVIE INC. | 2016-12-15 | — | — | US | disclosed |
| US-20160362431-A1 | Carbidopa And L-Dopa Prodrugs And Methods Of Use | ABBVIE INC. | 2016-12-15 | — | — | US | disclosed |
| US-9446059-B2 | Carbidopa and L-dopa prodrugs and methods of use | ABBVIE INC. (US) | 2016-09-20 | — | — | US | disclosed |
| US-9446059-B2 | Carbidopa and L-dopa prodrugs and methods of use | ABBVIE INC. (US) | 2016-09-20 | — | — | US | disclosed |
| US-20160106765-A1 | Carbidopa and L-Dopa Prodrugs and Methods of Use | ABBVIE INC. | 2016-04-21 | — | — | US | disclosed |
| US-20160106765-A1 | Carbidopa and L-Dopa Prodrugs and Methods of Use | ABBVIE INC. | 2016-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160362431-A1 | Carbidopa And L-Dopa Prodrugs And Methods Of Use | COMT, SNCA, PARK7 | SLC7A5 570/4885PTGS1 1240/4885KDM4E 3728/4885 |
| US-20220153765-A1 | METHODS OF TREATING PARKINSON'S DISEASE | SNCA, PARK7, COMT | SLC7A5 1753/4885PTGS1 900/4885KDM4E 3990/4885 |
| US-20160106765-A1 | Carbidopa and L-Dopa Prodrugs and Methods of Use | COMT, SNCA, PARK7 | SLC7A5 570/4885PTGS1 1240/4885KDM4E 3728/4885 |
| US-20240024338-A1 | CARBIDOPA AND L-DOPA PRODRUGS AND METHODS OF USE | COMT, SNCA, PARK7 | SLC7A5 570/4885PTGS1 1240/4885KDM4E 3728/4885 |
| US-11091507-B2 | Methods of treating Parkinson's disease | SNCA, PARK7, COMT | SLC7A5 1753/4885PTGS1 900/4885KDM4E 3990/4885 |
| US-10730895-B2 | Carbidopa prodrug | SNCA, PARK7, COMT | SLC7A5 985/4885PTGS1 1133/4885KDM4E 3875/4885 |
| US-10174061-B2 | Carbidopa and L-dopa prodrugs and methods of use | COMT, SNCA, PARK7 | SLC7A5 570/4885PTGS1 1240/4885KDM4E 3728/4885 |
| US-20200262852-A1 | CARBIDOPA PRODRUGS | SNCA, PARK7, COMT | SLC7A5 820/4885PTGS1 1065/4885KDM4E 3949/4885 |
| US-20180079762-A1 | Carbidopa and L-Dopa Prodrugs and Methods of use | COMT, SNCA, PARK7 | SLC7A5 570/4885PTGS1 1240/4885KDM4E 3728/4885 |
| US-20230157985-A1 | METHODS FOR TREATMENT OF PARKINSON'S DISEASE | DDC, DDT, COMT | SLC7A5 703/4885PTGS1 1666/4885KDM4E 3787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.